- Oops!Something went wrong.Please try again later.
HIV patients already enrolled in the trial will continue to receive the companies' combination therapy.
A Raleigh drugmaker is trying to advance the development program of its Covid-19 candidate after identifying positive results among a specific patient population.
A closer look at the clinical trial results that drove the stock up in October was a little disappointing.
Biogen Inc. is reportedly concocting a restructuring plan that would result in the termination of more than 1,000 employees.
Good news about a booster dose with the omicron variant could be bad news for the biotech's future sales.
The benchmark SPDR S&P Biotech ETF (NYSEMKT: XBI) recently started to recover, but it's still down more than 33% from a peak it reached this February. Editas Medicine (NASDAQ: EDIT) shares are down a whopping 54% over the past three months. It's been falling harder than most biotech stocks this year thanks to disappointing clinical trial results for its lead candidate, EDIT-101.
Shares of Novavax (NASDAQ: NVAX) were soaring 24.1% higher as of 12:35 p.m. ET on Tuesday. European Medicines Agency head Emma Cooke told European Union health ministers on Tuesday that Novavax's COVID-19 vaccine could be authorized in the "near future." Also, a study led by the University of Oxford found that a second dose of Novavax's vaccine following an initial dose of AstraZeneca's (NASDAQ: AZN) vaccine was significantly more effective than two doses of the AstraZeneca vaccine.
The company is no longer cheaply valued in the market, but the outlook remains positive
Vaccine stocks were muted Tuesday after test results indicated omicron might elude some of the protection provided by Pfizer's Covid shot.
Shares of Moderna (NASDAQ: MRNA) were rising 3.1% as of 12:51 p.m. ET. The gain came after results were announced for a COVID-19 vaccine study led by the University of Oxford. This study found that a second dose of Moderna's vaccine following a first dose of either the Pfizer-BioNTech vaccine or the AstraZeneca vaccine was more effective than two doses of the two other vaccines.
Pfizer and BioNTech said Wednesday a booster Covid shot is necessary to tackle the omicron variant —but the vaccine stocks fell.
Is Pfizer stock a buy after a new Covid variant emerged that partially eludes protection from its Covid shot? Is PFE stock a buy right now?
Data from a small study showed BioNTech/Pfizer's Covid-19 vaccine is effectively a three-dose regimen against Omicron, said BioNTech CEO Dr. Ugur Sahin.
It has been a volatile couple of weeks for Covid-19 vaccine makers, as investors battle to assess the impact of the Omicron variant while waiting for answers to crucial questions.
Biotech giant Gilead Sciences (NASDAQ: GILD) is a good example. With that in mind, let's look into what's going on with Gilead Sciences right now and whether it is worth purchasing its shares. Gilead Sciences' shares have performed on par with the broader market this year.
With a few exceptions for emergency or urgent care, Medicare plans will only cover you within the U.S. and its territories. But should you maintain your coverage when you move abroad? Expert Ron Elledge answers some common questions.
Nearly two years into the pandemic, doctors have few effective treatments for patients, especially early in the disease. But some therapies have been shown to work in clinical studies.
U.S.-listed shares of AstraZeneca were up 0.3% in after-hours trading on Wednesday after the Food and Drug Administration authorized the company's COVID-19 monoclonal antibodies for pre-exposure prophylaxis in individuals who are immunocompromised or have a history of severe adverse reactions to a COVID-19 vaccine. In both instances, the individuals, who must be at least 12 years old, may not be able to gain protective antibodies through COVID-19 vaccination. This is the first authorization for
A third shot of the Pfizer vaccine provides robust protection against the Omicron variant of the coronavirus, the company's CEO revealed, adding to a growing — if early — sense that even if the new strain is more transmissible, it does not pose the degree of danger some initially feared.
The latest batch of preliminary data indicates that COVID-19 booster shots are likely what is needed to further protect against the omicron variant.
British pharma giant GlaxoSmithKline and Canada's Medicago said on Tuesday they had seen positive results with a candidate Covid-19 vaccine in a large-scale trial, although the tests were carried out before the Omicron variant emerged.